BNP Paribas Financial Markets
FULC icon

BNP Paribas Financial Markets’s Fulcrum Therapeutics FULC Stock Holding History

BNP Paribas Financial Markets’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$436K Buy
119,038
+104,891
+741% +$638K ﹤0.01% 3839
2026
Q1 		$109K Buy
14,147
+3,625
+34% +$33.6K ﹤0.01% 4337
2025
Q4 		$119K Sell
10,522
-3,752
-26% -$38.2K ﹤0.01% 4302
2025
Q3 		$131K Buy
14,274
+8,275
+138% +$59.9K ﹤0.01% 4183
2025
Q2 		$41.3K Sell
5,999
-9,587
-62% -$51.3K ﹤0.01% 4329
2025
Q1 		$44.9K Buy
15,586
+7,572
+94% +$27.8K ﹤0.01% 4326
2024
Q4 		$37.7K Buy
+8,014
New +$29.6K ﹤0.01% 4539
2022
Q4 		– Sell
-9,551
Closed -$77.3K – 4252
2022
Q3 		$77.3K Buy
+9,551
New +$68.4K ﹤0.01% 3863

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
GP
GSK plc London $602M AUM

BNP Paribas Financial Markets's FULC Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Fulcrum Therapeutics (FULC) stake by 741% in Q2 2026, buying an estimated $638K and bringing the position to 119,038 shares worth $436K. The position accounts for ﹤0.01% of the portfolio, ranked #3839.

BNP Paribas Financial Markets first reported a position in FULC in Q3 2022 and has held it in 8 quarters since. 141 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • BNP Paribas Financial Markets held 119,038 shares of Fulcrum Therapeutics worth $436K as of Q2 2026.
  • BNP Paribas Financial Markets bought 104,891 Fulcrum Therapeutics shares in Q2 2026, an estimated $638K.
  • Fulcrum Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3839 holding.
  • BNP Paribas Financial Markets first reported a position in Fulcrum Therapeutics in Q3 2022 and has held it in 8 quarters since.
  • 141 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.